LA HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
A slimmer Avery Dennison Corp. on Wednesday announced fiscal first quarter results that were in line with Wall Street expectations for profit. Cheesecake Factory Inc. said Wednesday that same-store sales rose at most of its outlets during the fiscal first quarter but poor weather cut into profits. IPC disappoints. Defense cuts hit Teledyne. On Assignment meets forecasts.
Amgen Inc. on Tuesday reported a lower-than-expected first quarter profit, but said it plans to submit its experimental cholesterol drug for approval by the end of the year.
The U.S. Food and Drug Administration has granted fast-track designation for ivabradine, a heart drug licensed for sale by Amgen Inc. in Thousand Oaks.
The Illinois Attorney General’s Office on Thursday said that it is investigating allegations that Herbalife is running a pyramid scheme.
Smartphone maker BlackBerry announced Tuesday that it has invested in Dr. Patrick Soon-Shiong’s NantHealth with the hope that its smartphones can be married to the West L.A. billionaire’s next-generation medical information technology.
A report that both the U.S. Department of Justice and the FBI are investigating Herbalife sent shares of the nutritional supplement company sliding 14 percent on Friday.
Providence Saint Joseph Medical Center announced it is the first hospital in the nation to conduct an MRI scan of a patient with a new MRI-compatible heart pacemaker.
Trading in shares of GrowLife Inc. was halted Thursday for two weeks after the Securities and Exchange Commission questioned some of the company’s stock transactions.
Shares of Puma Biotechnology Inc. dropped 18 percent on Monday after the Westwood drug developer reported clinical trial results for its experimental breast cancer drug that were less dramatic than investors expected.
Shares of MannKind Corp. fell nearly 8 percent Monday after the company announced that the FDA’s final decision on its inhalable insulin could be delayed beyond an expected April 15 deadline.
BIOTECH: MannKind stock rises after its device receives FDA panel’s OK.
Shares of MannKind climb after its inhalable insulin device receives FDA panel’s approval.
Shares of Amgen Inc. fell 4 percent on Friday after the Thousand Oaks biotech giant said an experimental skin cancer drug had not significantly improved survival rates in clinical trial patients although it reduced the size of tumors.
Amgen Inc. on Thursday said it would pay GlaxoSmithKline more than $275 million to get out of a co-marketing agreement with the British drug company to promote Amgen’s osteoporosis drug Prolia in certain regions outside the United States.
Shares of Response Genetics Inc. jumped 18 percent on Thursday after the cancer diagnostic test company signed agreements with six additional health plans and two large health care groups.
MannKind Corp.'s share price more than doubled in after-hours trading Tuesday, following news that an FDA advisory panel had finally recommended approval of the Valencia company's Afrezza insulin inhaler.